Advertisement

AAPS PharmSciTech

, Volume 19, Issue 7, pp 2851–2858 | Cite as

Physiologically Based Absorption Modeling of Salts of Weak Bases Based on Data in Hypochlorhydric and Achlorhydric Biorelevant Media

  • Filippos Kesisoglou
  • Maria Vertzoni
  • Christos Reppas
Research Article Theme: Advancements in Dissolution Testing of Oral and Non-Oral Formulations
Part of the following topical collections:
  1. Theme: Advancements in Dissolution Testing of Oral and Non-Oral Formulations

Abstract

Physiologically based absorption modeling has been attracting increased attention to study the interactions of weakly basic drug compounds with acid-reducing agents like proton-pump inhibitors and H2 blockers. Recently, standardized gastric and intestinal biorelevant media to simulate the achlorhydric and hypochlorhydric stomach were proposed and solubility and dissolution data for two model compounds were generated. In the current manuscript, for the first time, we report the utility of these recently proposed biorelevant media as input into physiologically based absorption modeling. Where needed, data collected with the biorelevant gastrointestinal transfer (BioGIT) system were used for informing the simulations in regard to the precipitation kinetics. Using two model compounds, a HCl salt and a semi-fumarate co-crystal which as expected dissolve to a greater extent in these media (and in gastric and intestinal human aspirates) compared to what the pH–solubility profile of the free form would suggest, we demonstrate successful description of the plasma concentration profiles and correctly predicted the lack of significant interaction after administration with pantoprazole or famotidine, respectively. Thus, the data reported in this manuscript represent an initial step towards defining biorelevant input for such simulations on interactions with acid-reducing agents.

KEY WORDS

physiologically based absorption modeling hypochlorhydria achlorhydria biorelevant media GastroPlus 

Notes

Acknowledgements

Authors would like to thank Ms. Chara Litou for her contribution to the BioGIT experiments. Part of the work presented in this manuscript was presented at the annual EDAN meeting, Leuven, Belgium, 11–13 March 2018.

References

  1. 1.
    Mitra A, Kesisoglou F, Beauchamp M, Zhu W, Chiti F, Wu Y. Using absorption simulation and gastric pH modulated dog model for formulation development to overcome achlorhydria effect. Mol Pharm. 2011;8(6):2216–23.CrossRefGoogle Scholar
  2. 2.
    Bhattachar SN, Perkins EJ, Tan JS, Burns LJ. Effect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus™ simulations to predict absorption. J Pharm Sci. 2011;100(11):4756–65.CrossRefGoogle Scholar
  3. 3.
    Chung J, Alvarez-Nunez F, Chow V, Daurio D, Davis J, Dodds M, et al. Utilizing physiologically based pharmacokinetic modeling to inform formulation and clinical development for a compound with pH-dependent solubility. J Pharm Sci. 2015;104(4):1522–32.  https://doi.org/10.1002/jps.24339.CrossRefPubMedGoogle Scholar
  4. 4.
    Parrott NJ, Yu LJ, Takano R, Nakamura M, Morcos PN. Physiologically based absorption modeling to explore the impact of food and gastric pH changes on the pharmacokinetics of alectinib. AAPS J. 2016;18(6):1464–74.CrossRefGoogle Scholar
  5. 5.
    FARYDAK®. Clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205353Orig1s000ClinPharmR.pdf. Accessed on 06 Dec 2017.
  6. 6.
    Cristofoletti R, Patel N, Dressman JB. Assessment of bioequivalence of weak base formulations under various dosing conditions using physiologically based pharmacokinetic simulations in virtual populations. Case examples: ketoconazole and posaconazole. J Pharm Sci. 2017;106(2):560–9.CrossRefGoogle Scholar
  7. 7.
    Lu T, Fraczkiewicz G, Salphati L, Budha N, Dalziel G, Smelick GS, et al. Combining “bottom-up” and “top-down” approaches to assess the impact of food and gastric pH on pictilisib (GDC-0941) pharmacokinetics. CPT Pharmacometrics Syst Pharmacol. 2017;6:747–55.  https://doi.org/10.1002/psp4.12228.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Seiler D, Doser K, Salem I. Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor. Arzneimittelforschung. 2011;61(4):247–51.CrossRefGoogle Scholar
  9. 9.
    Doki K, Darwich AS, Patel N, Rostami-Hodjegan A. Virtual bioequivalence for achlorhydric subjects: the use of PBPK modelling to assess the formulation-dependent effect of achlorhydria. Eur J Pharm Sci. 2017;109:111–20.CrossRefGoogle Scholar
  10. 10.
    Litou C, Vertzoni M, Xu W, Kesisoglou F, Reppas C. The impact of reduced gastric acid secretion on dissolution of salts of weak bases in the fasted upper gastrointestinal lumen: data in biorelevant media and in human aspirates. Eur J Pharm Biopharm. 2017;115:94–101.  https://doi.org/10.1016/j.ejpb.2017.02.009.CrossRefPubMedGoogle Scholar
  11. 11.
    Kourentas A, Vertzoni M, Stavrinoudakis N, Symillidis A, Brouwers J, Augustijns P, et al. An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: design, implementation, and evaluation. Eur J Pharm Sci. 2016;82:106–14.  https://doi.org/10.1016/j.ejps.2015.11.012.CrossRefPubMedGoogle Scholar
  12. 12.
    Markopoulos C, Andreas C, Vertzoni M, Dressman J, Reppas C. In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: choosing the appropriate test media. Eur J Pharm Biopharm. 2015;93:173–82.CrossRefGoogle Scholar
  13. 13.
    Kesisoglou F, Mitra A. Application of absorption modeling in rational design of drug product under quality-by-design paradigm. AAPS J. 2015;17(5):1224–36.  https://doi.org/10.1208/s12248-015-9781-1.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Tsume Y, Amidon GL, Takeuchi S. Dissolution effect of gastric and intestinal pH for a BCS class II drug, pioglitazone: new in vitro dissolution system to predict in vivo dissolution. J Bioequiv Availab. 2013;5(6):224–7.CrossRefGoogle Scholar
  15. 15.
    Ding X, Gueorguieva I, Wesley JA, Burns LJ, Coutant CA. Assessment of in vivo clinical product performance of a weak basic drug by integration of in vitro dissolution tests and physiologically based absorption modeling. AAPS J. 2015;17(6):1395–406.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Litou C, Vertzoni M, Goumas C, Vasdekis V, Xu W, Kesisoglou F, et al. Characteristics of the human upper gastrointestinal contents in the fasted state under hypo- and a-chlorhydric gastric conditions under conditions of typical drug-drug interaction studies. Pharm Res. 2016;33(6):1399–412.CrossRefGoogle Scholar
  17. 17.
    Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, et al. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:300–21.  https://doi.org/10.1016/j.ejps.2013.09.008.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Filippos Kesisoglou
    • 1
  • Maria Vertzoni
    • 2
  • Christos Reppas
    • 2
  1. 1.Pharmaceutical SciencesMerck & Co, Inc.West PointUSA
  2. 2.Department of PharmacyNational and Kapodistrian University of AthensZografouGreece

Personalised recommendations